Study: Dyax drug lessens symptoms of hereditary angioedema

08/18/2008 | Forbes

Dyax's experimental treatment for hereditary angioedema, DX-88, reduced symptoms of the genetic blood disease in 93.8% of patients who were injected with the drug during a late-stage trial, researchers reported. Dyax is in talks with Dompe Farmaceutici to partner on DX-88 in Europe.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ